# Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

> **NCT02478502** · PHASE2 · TERMINATED · sponsor: **University Hospital, Akershus** · enrollment: 14 (actual)

## Conditions studied

- Testicular Cancer

## Interventions

- **DRUG:** cabazitaxel

## Key facts

- **NCT ID:** NCT02478502
- **Lead sponsor:** University Hospital, Akershus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Insufficient recruitment
- **Last updated:** 2024-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02478502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02478502, "Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02478502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*